Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Alterity Therapeutics ( (ATHE) ) has shared an update.
In January 2025, Alterity Therapeutics released a shareholder newsletter detailing significant progress in 2024, including the completion of a Phase 2 clinical trial for ATH434. Encouraging preliminary results from a biomarker study showed promise in treating Multiple System Atrophy, with stable or improved clinical measures. The newsletter highlighted further advancements, such as preclinical data demonstrating ATH434’s potential in Parkinson’s disease and the development of a novel imaging biomarker. The company anticipates pivotal data from ongoing trials this year, reinforcing its commitment to innovative therapies for neurodegenerative conditions.
More about Alterity Therapeutics
Alterity Therapeutics is a clinical stage biotechnology company focused on developing treatments for neurodegenerative diseases. Their lead asset, ATH434, targets Parkinsonian disorders and is in Phase 2 clinical trials for Multiple System Atrophy. The company operates from Melbourne, Australia, and San Francisco, USA.
YTD Price Performance: -8.31%
Average Trading Volume: 70,248
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $28.18M
Find detailed analytics on ATHE stock on TipRanks’ Stock Analysis page.
